Our results showed that Trichomicin significantly suppressed tumor activity in a CRC xenograft model by downregulating the expression of IL-6 and TNFα, which resulted in inhibition of the expression of the immune check point ligand protein, PD-L1, through inhibition of the Stat3 and NF-κB signaling pathways. The gene discussed is NFKB1; the disease is colorectal carcinoma.